KR20020084107A - 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 - Google Patents

위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 Download PDF

Info

Publication number
KR20020084107A
KR20020084107A KR1020027009850A KR20027009850A KR20020084107A KR 20020084107 A KR20020084107 A KR 20020084107A KR 1020027009850 A KR1020027009850 A KR 1020027009850A KR 20027009850 A KR20027009850 A KR 20027009850A KR 20020084107 A KR20020084107 A KR 20020084107A
Authority
KR
South Korea
Prior art keywords
binding molecule
amino acid
tyr
acid sequence
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027009850A
Other languages
English (en)
Korean (ko)
Inventor
아담한스요에르그
파르베르로타르
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20020084107A publication Critical patent/KR20020084107A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027009850A 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도 Ceased KR20020084107A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
GB0007911.1 2000-03-30
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087020504A Division KR20080079702A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Publications (1)

Publication Number Publication Date
KR20020084107A true KR20020084107A (ko) 2002-11-04

Family

ID=9888901

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020027009850A Ceased KR20020084107A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도
KR1020087020504A Ceased KR20080079702A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087020504A Ceased KR20080079702A (ko) 2000-03-30 2001-03-28 위장관 염증 질환의 치료에서 ｃｄ25 결합 분자의 용도

Country Status (18)

Country Link
US (2) US20050226872A1 (https=)
EP (1) EP1268553A1 (https=)
JP (1) JP2003528890A (https=)
KR (2) KR20020084107A (https=)
CN (1) CN1416432A (https=)
AU (2) AU4651601A (https=)
BR (1) BR0109549A (https=)
CA (1) CA2401249A1 (https=)
GB (1) GB0007911D0 (https=)
HU (1) HUP0301846A3 (https=)
IL (1) IL151089A0 (https=)
NO (1) NO20024579L (https=)
NZ (1) NZ520547A (https=)
PL (1) PL357014A1 (https=)
RU (1) RU2286797C2 (https=)
SK (1) SK13892002A3 (https=)
WO (1) WO2001072845A1 (https=)
ZA (1) ZA200207736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502593A (ja) * 2001-04-06 2005-01-27 ユニバーシティ・オブ・ブリストル ステロイド耐性患者におけるｃｄ２５結合分子の使用
CA2711843C (en) * 2007-12-20 2018-11-13 Laboratory Corporation Of America Holdings Her-2 diagnostic methods
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172984A1 (en) * 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-2 expression
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas

Also Published As

Publication number Publication date
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
RU2002127800A (ru) 2004-03-27
NO20024579L (no) 2002-11-11
AU4651601A (en) 2001-10-08
WO2001072845A1 (en) 2001-10-04
US20090041775A1 (en) 2009-02-12
HUP0301846A3 (en) 2010-07-28
HUP0301846A2 (hu) 2003-09-29
RU2286797C2 (ru) 2006-11-10
CN1416432A (zh) 2003-05-07
ZA200207736B (en) 2003-05-08
PL357014A1 (en) 2004-07-12
SK13892002A3 (sk) 2003-05-02
JP2003528890A (ja) 2003-09-30
KR20080079702A (ko) 2008-09-01
IL151089A0 (en) 2003-04-10
NO20024579D0 (no) 2002-09-24
EP1268553A1 (en) 2003-01-02
NZ520547A (en) 2005-04-29
GB0007911D0 (en) 2000-05-17
BR0109549A (pt) 2003-06-10

Similar Documents

Publication Publication Date Title
US20090041775A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
JP7575102B2 (ja) Ｍｕｃ１８に特異的な抗体
CN109963592B (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP7623939B2 (ja) 葉酸受容体アルファに特異的な抗体
TW200815468A (en) Use of organic compounds
JP7578289B2 (ja) Ｍｕｃ１８に特異的な抗体
EA006314B1 (ru) Способ ингибирования прогрессивного развития или стабилизации волчаночного нефрита
WO2019051164A1 (en) ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
KR20190090894A (ko) 관절염 치료
CN115551886A (zh) 用于ttr淀粉样变性的联合疗法
AU2001246516A1 (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
US20220111008A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
JP2003528890A5 (https=)
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
JP2026504943A (ja) 併用療法のための方法および組成物
EP4594359A2 (en) Antibodies binding to leukocyte immunoglobulin-like receptor subfamily b member 2 (lilrb2) and uses thereof
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CN112439060B (zh) Pd-l1免疫疗法的新用途
KR20240004761A (ko) 항-baffr 항체를 사용한 전신 홍반성 루푸스의 치료

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020731

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070322

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080422

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070322

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080723

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080422

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20100330

Appeal identifier: 2008101007194

Request date: 20080723

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080821

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080821

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080723

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080122

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20090102

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080723

Effective date: 20100330

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20100330

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080723

Decision date: 20100330

Appeal identifier: 2008101007194